Jasper Ridge Partners’s Agile Therapeutics AGRX Stock Holding History

Jasper Ridge Partners’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-6	Closed	-$93K	–	95
2016 Q2	$93K	Buy	+6	New	+$82.2K	0.01%	91

Other funds holding AGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jasper Ridge Partners's AGRX Position: Q3 2016 in Review

Jasper Ridge Partners sold out of Agile Therapeutics (AGRX) in Q3 2016, closing a stake of 6 shares — an estimated $93K sold.

Jasper Ridge Partners first reported a position in AGRX in Q2 2016 and held it in 1 quarter. The position peaked at $93K in Q2 2016. 51 funds tracked by Wall St. Rank hold AGRX as of Q3 2016.

Jasper Ridge Partners reported no remaining Agile Therapeutics position as of Q3 2016 after selling out during the quarter.
Jasper Ridge Partners sold 6 Agile Therapeutics shares in Q3 2016, an estimated $93K.
Jasper Ridge Partners first reported a position in Agile Therapeutics in Q2 2016 and held it in 1 quarter.
Jasper Ridge Partners's Agile Therapeutics position peaked at $93K in Q2 2016.
51 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2016.

Based on Jasper Ridge Partners's 13F filing for Q3 2016, filed 14 Nov 2016.